Gene Review:
CYP2D6 - cytochrome P450, family 2, subfamily D,...
Homo sapiens
Synonyms:
CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, ...
Matthew P. Goetz,
Daniel J. Schaid,
D. Lawrence Wickerham,
Stephanie Safgren,
Taisei Mushiroda,
Michiaki Kubo,
Anthony Batzler,
Joseph P. Costantino,
Victor G. Vogel,
Soonmyung Paik,
Erin E. Carlson,
David A. Flockhart,
Norman Wolmark,
Yusuke Nakamura,
Richard M. Weinshilboum,
James N. Ingle,
Matthew M. Ames,
Ching,
Blake,
Ghabrial,
Angus,
Malek,
Akutsu,
Sakurada,
Furihata,
Kobayashi,
Ikegaya,
Chiba,
LLerena,
de la Rubia,
Dorado,
Berecz,
Becquemont,
Broly,
Poupon,
Poirier,
Serfaty,
Chazouilleres,
Funck-Brentano,
Jaillon,
Mizutani,
Osaka,
Hattori,
Usui,
Shinoda,
Kuno,
Tanaka,
Kuno,
Christensen,
Mirghani,
Yaşar,
Nordmark,
Wahlberg,
Tybring,
Bertilsson,
Dalén,
Andersson,
Muirhead,
Bolot Kalmyrzaev,
Wienkers,
Wynalda,
McGinnity,
Grime,
Kenny,
Riley,
Berry,
Kirchheiner,
Meisel,
Roots,
Kudlicz,
Bauer,
Meineke,
Brockmöller,
Chalon,
Desante,
Long,
Golnez,
Smith,
Sauer,
Witcher,
Horsmans,
Desager,
Thomasson,
Frye,
Voorman,
Wang,
Koeplinger,
Zhao,
Payne,
Maio,
Voorman,
Payne,
Hauer,
Wienkers,
Sanders,
Gardiner,
Begg,
- CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Dehal, S.S., Kupfer, D. Cancer Res. (1997)
- Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Becquemont, L., Chazouilleres, O., Serfaty, L., Poirier, J.M., Broly, F., Jaillon, P., Poupon, R., Funck-Brentano, C. Clin. Pharmacol. Ther. (2002)
- Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Desta, Z., Zhao, X., Shin, J.G., Flockhart, D.A. Clinical pharmacokinetics. (2002)
- Expression of cytochrome P450 and microsomal epoxide hydrolase in cervical and oral epithelial cells immortalized by human papillomavirus type 16 E6/E7 genes. Farin, F.M., Bigler, L.G., Oda, D., McDougall, J.K., Omiecinski, C.J. Carcinogenesis (1995)
- CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Silvestri, L., Sonzogni, L., De Silvestri, A., Gritti, C., Foti, L., Zavaglia, C., Leveri, M., Cividini, A., Mondelli, M.U., Civardi, E., Silini, E.M. Int. J. Cancer (2003)
- CYP2D6 gene variants and their association with breast cancer susceptibility. Abraham, J.E., Maranian, M.J., Driver, K.E., Platte, R., Kalmyrzaev, B., Baynes, C., Luccarini, C., Earl, H.M., Dunning, A.M., Pharoah, P.D., Caldas, C. Cancer. Epidemiol. Biomarkers. Prev. (2011)
- Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Goetz, M.P., Schaid, D.J., Wickerham, D.L., Safgren, S., Mushiroda, T., Kubo, M., Batzler, A., Costantino, J.P., Vogel, V.G., Paik, S., Carlson, E.E., Flockhart, D.A., Wolmark, N., Nakamura, Y., Weinshilboum, R.M., Ingle, J.N., Ames, M.M. Clin. Cancer Res. (2011)
- ApoE and CYP2D6 polymorphism with and without parkinsonism-dementia complex in the people of Chamorro, guam. Chen, X., Xia, Y., Gresham, L.S., Molgaard, C.A., Thomas, R.G., Galasko, D., Wiederholt, W.C., Saitoh, T. Neurology (1996)
- CYP2D6 polymorphisms in Alzheimer's disease, with and without extrapyramidal signs, showing no apolipoprotein E epsilon 4 effect modification. Cervilla, J.A., Russ, C., Holmes, C., Aitchison, K., Smith, C.A., Powell, J., Lovestone, S. Biol. Psychiatry (1999)
- Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Chalon, S.A., Desager, J.P., Desante, K.A., Frye, R.F., Witcher, J., Long, A.J., Sauer, J.M., Golnez, J.L., Smith, B.P., Thomasson, H.R., Horsmans, Y. Clin. Pharmacol. Ther. (2003)
- Relevance of deficient CYP2D6 in opiate dependence. Mikus, G., Mörike, K., Griese, E.U., Klotz, U. Pharmacogenetics (1998)
- Nicotine metabolism and CYP2D6 phenotype in smokers. Caporaso, N.E., Lerman, C., Audrain, J., Boyd, N.R., Main, D., Issaq, H.J., Utermahlan, B., Falk, R.T., Shields, P. Cancer Epidemiol. Biomarkers Prev. (2001)
- Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Gardiner, S.J., Begg, E.J. Pharmacol. Rev. (2006)
- Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. Kato, S., Bowman, E.D., Harrington, A.M., Blomeke, B., Shields, P.G. J. Natl. Cancer Inst. (1995)
- Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. Evans, W.E., Relling, M.V., Rahman, A., McLeod, H.L., Scott, E.P., Lin, J.S. J. Clin. Invest. (1993)
- Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Voorman, R.L., Payne, N.A., Wienkers, L.C., Hauer, M.J., Sanders, P.E. Drug Metab. Dispos. (2001)
- Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. Tanaka, E. Journal of clinical pharmacy and therapeutics. (1998)
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.H., Skaar, T., Storniolo, A.M., Li, L., Araba, A., Blanchard, R., Nguyen, A., Ullmer, L., Hayden, J., Lemler, S., Weinshilboum, R.M., Rae, J.M., Hayes, D.F., Flockhart, D.A. J. Natl. Cancer Inst. (2005)
- QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. LLerena, A., Berecz, R., de la Rubia, A., Dorado, P. J. Psychopharmacol. (Oxford) (2002)
- Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Voorman, R.L., Maio, S.M., Hauer, M.J., Sanders, P.E., Payne, N.A., Ackland, M.J. Drug Metab. Dispos. (1998)
- The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Kimura, S., Umeno, M., Skoda, R.C., Meyer, U.A., Gonzalez, F.J. Am. J. Hum. Genet. (1989)
- Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Longuemaux, S., Deloménie, C., Gallou, C., Méjean, A., Vincent-Viry, M., Bouvier, R., Droz, D., Krishnamoorthy, R., Galteau, M.M., Junien, C., Béroud, C., Dupret, J.M. Cancer Res. (1999)
- Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Brockmöller, J., Cascorbi, I., Kerb, R., Roots, I. Cancer Res. (1996)
- Development of human cytochrome P450-expressing cell lines: application in mutagenicity testing of ochratoxin A. de Groene, E.M., Hassing, I.G., Blom, M.J., Seinen, W., Fink-Gremmels, J., Horbach, G.J. Cancer Res. (1996)
- Role of CYP2D6 in the N-hydroxylation of procainamide. Lessard, E., Fortin, A., Bélanger, P.M., Beaune, P., Hamelin, B.A., Turgeon, J. Pharmacogenetics (1997)
- Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Kreth, K., Kovar, K., Schwab, M., Zanger, U.M. Biochem. Pharmacol. (2000)
- Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Mizutani, T., Shinoda, M., Tanaka, Y., Kuno, T., Hattori, A., Usui, T., Kuno, N., Osaka, T. Drug Metab. Rev. (2005)
- Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. McGinnity, D.F., Berry, A.J., Kenny, J.R., Grime, K., Riley, R.J. Drug Metab. Dispos. (2006)
- Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Chang, T.K., Weber, G.F., Crespi, C.L., Waxman, D.J. Cancer Res. (1993)
- Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. Paine, M.J., McLaughlin, L.A., Flanagan, J.U., Kemp, C.A., Sutcliffe, M.J., Roberts, G.C., Wolf, C.R. J. Biol. Chem. (2003)
- The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Christensen, M., Andersson, K., Dalén, P., Mirghani, R.A., Muirhead, G.J., Nordmark, A., Tybring, G., Wahlberg, A., Yaşar, U., Bertilsson, L. Clin. Pharmacol. Ther. (2003)
- Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Kashuba, A.D., Nafziger, A.N., Kearns, G.L., Leeder, J.S., Gotschall, R., Rocci, M.L., Kulawy, R.W., Beck, D.J., Bertino, J.S. Clin. Pharmacol. Ther. (1998)
- CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Schroth, W., Hamann, U., Fasching, P.A., Dauser, S., Winter, S., Eichelbaum, M., Schwab, M., Brauch, H. Clin. Cancer Res. (2010)
- A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay. Yamamoto, A.M., Johanet, C., Duclos-Vallee, J.C., Bustarret, F.A., Alvarez, F., Homberg, J.C., Bach, J.F. Clin. Exp. Immunol. (1997)
- Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450. Zhou, L., Erickson, R.R., Hardwick, J.P., Park, S.S., Wrighton, S.A., Holtzman, J.L. J. Pharmacol. Exp. Ther. (1997)
- Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Akutsu, T., Kobayashi, K., Sakurada, K., Ikegaya, H., Furihata, T., Chiba, K. Drug Metab. Dispos. (2007)
- Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. Kusumoto, M., Ueno, K., Oda, A., Takeda, K., Mashimo, K., Takaya, K., Fujimura, Y., Nishihori, T., Tanaka, K. Clin. Pharmacol. Ther. (2001)
- The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. Yu, A.M., Granvil, C.P., Haining, R.L., Krausz, K.W., Corchero, J., Küpfer, A., Idle, J.R., Gonzalez, F.J. J. Pharmacol. Exp. Ther. (2003)
- CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy. Yan, F.X., Langub, M.C., Ihnen, M.A., Hornung, C., Juronen, E., Rayens, M.K., Cai, W.M., Wedlund, P.J., Fanti, P. British journal of clinical pharmacology. (2003)
- Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone. Prost, F., Thormann, W. Electrophoresis (2003)
- Involvement of CYP1A2 in mexiletine metabolism. Nakajima, M., Kobayashi, K., Shimada, N., Tokudome, S., Yamamoto, T., Kuroiwa, Y. British journal of clinical pharmacology. (1998)
- Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Wienkers, L.C., Wynalda, M.A. Drug Metab. Dispos. (2002)
- Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. Voorman, R.L., Maio, S.M., Payne, N.A., Zhao, Z., Koeplinger, K.A., Wang, X. J. Pharmacol. Exp. Ther. (1998)
- Differential inhibition of human CYP1A1 and CYP1A2 by quinidine and quinine. Ching, M.S., Blake, C.L., Malek, N.A., Angus, P.W., Ghabrial, H. Xenobiotica (2001)
- The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Fontana, R.J., Turgeon, D.K., Woolf, T.F., Knapp, M.J., Foster, N.L., Watkins, P.B. Hepatology (1996)
- Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Gasser, T., Wszolek, Z.K., Trofatter, J., Ozelius, L., Uitti, R.J., Lee, C.S., Gusella, J., Pfeiffer, R.F., Calne, D.B., Breakefield, X.O. Ann. Neurol. (1994)
- Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Chainuvati, S., Nafziger, A.N., Leeder, J.S., Gaedigk, A., Kearns, G.L., Sellers, E., Zhang, Y., Kashuba, A.D., Rowland, E., Bertino, J.S. Clin. Pharmacol. Ther. (2003)
- In vivo effects of interleukin-10 on human cytochrome P450 activity. Gorski, J.C., Hall, S.D., Becker, P., Affrime, M.B., Cutler, D.L., Haehner-Daniels, B. Clin. Pharmacol. Ther. (2000)
- Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Kirchheiner, J., Kudlicz, D., Meisel, C., Bauer, S., Meineke, I., Roots, I., Brockmöller, J. Clin. Pharmacol. Ther. (2003)
- A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. Bork, J.A., Rogers, T., Wedlund, P.J., de Leon, J. The Journal of clinical psychiatry. (1999)
- Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity. Flanagan, J.U., McLaughlin, L.A., Paine, M.J., Sutcliffe, M.J., Roberts, G.C., Wolf, C.R. Biochem. J. (2003)
- Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Ellis, S.W., Ching, M.S., Watson, P.F., Henderson, C.J., Simula, A.P., Lennard, M.S., Tucker, G.T., Woods, H.F. Biochem. Pharmacol. (1992)
- Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Cribb, A., Nuss, C., Wang, R. Drug Metab. Dispos. (1995)
- CYP2B6, CYP2D6, and CYP3A4 Catalyze the Primary Oxidative Metabolism of Perhexiline Enantiomers by Human Liver Microsomes. Davies, B.J., Coller, J.K., Somogyi, A.A., Milne, R.W., Sallustio, B.C. Drug Metab. Dispos. (2007)
- CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Abraham, J.E., Maranian, M.J., Driver, K.E., Platte, R., Kalmyrzaev, B., Baynes, C., Luccarini, C., Shah, M., Ingle, S., Greenberg, D., Earl, H.M., Dunning, A.M., Pharoah, P.D., Caldas, C. Breast. Cancer. Res. (2010)